Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Harmony Biosciences Holdings

Healthcare US HRMY

32.66USD
0.56(1.74%)

Last update at 2026-06-04T17:48:00Z

Day Range

32.4132.97
LowHigh

52 Week Range

18.6139.27
LowHigh

Fundamentals

  • Previous Close 32.10
  • Market Cap1670.82M
  • Volume193134
  • P/E Ratio12.90
  • Dividend Yield-%
  • EBITDA228.06M
  • Revenue TTM617.51M
  • Revenue Per Share TTM10.52
  • Gross Profit TTM 354.37M
  • Diluted EPS TTM2.28

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 104.69M 37.43M -36.94400M -151.97700M -39.89800M
Minority interest - - - - -
Net income 181.47M 34.60M -51.85600M -158.05000M -39.89800M
Selling general administrative 84.02M 63.91M 39.75M 36.41M 12.21M
Selling and marketing expenses 79.28M 68.12M 55.82M 44.32M 16.86M
Gross profit 354.37M 249.92M 132.00M 4.42M 0.00000M
Reconciled depreciation 23.39M 18.84M 10.24M 3.21M 0.18M
Ebit 120.19M 68.70M 3.68M -145.90400M -41.43900M
Ebitda 120.36M 87.54M 13.91M -142.69400M -41.25500M
Depreciation and amortization 0.17M 18.84M 10.24M 3.21M 0.18M
Non operating income net other 0.17M -26.13000M -25.71000M - -
Operating income 120.19M 68.70M 3.68M -145.90400M -41.43900M
Other operating expenses 317.67M 217.91M 142.76M 151.90M 41.44M
Interest expense 15.67M 23.97M 28.22M 0.00000M 0.00000M
Tax provision -76.78200M 2.83M 0.00000M 0.00000M 0.00000M
Interest income - - - - -
Net interest income -15.66900M -23.97000M -28.22000M -6.07300M 1.54M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -76.78200M 2.83M 14.91M 6.07M 1.54M
Total revenue 437.86M 305.44M 159.74M 6.00M 0.00000M
Total operating expenses 234.19M 162.39M 115.02M 150.32M 41.44M
Cost of revenue 83.48M 55.52M 27.74M 1.58M 0.00000M
Total other income expense net -15.50000M -31.27600M -40.62200M -6.07300M 1.54M
Discontinued operations - - - - -
Net income from continuing ops 181.47M 34.60M -36.94400M -151.97700M -39.89800M
Net income applicable to common shares 181.47M 34.60M -63.84800M -187.20800M -70.08300M
Preferred stock and other adjustments - - 26.90M - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 811.45M 673.87M 433.44M 427.07M 106.70M
Intangible assets 137.11M 160.95M 143.92M 162.34M 72.19M
Earning assets - - - - -
Other current assets 5.54M 8.79M 3.22M 1.30M 0.26M
Total liab 344.46M 271.03M 246.94M 329.89M 118.29M
Total stockholder equity 466.99M 402.84M 186.51M 97.18M -11.58500M
Deferred long term liab - - - 0.21M -
Other current liab 7.81M 73.10M 1.36M 131.98M 13.53M
Common stock 0.00100M 0.00100M 0.00100M 0.00100M 0.00100M
Capital stock 0.00100M 0.00100M 0.00100M 0.00100M 411.28M
Retained earnings -143.27700M -272.13000M -453.59800M -488.19500M -422.86200M
Other liab - 1.53M 3.18M 1.10M 0.45M
Good will - - - - -
Other assets - 87.18M 4.26M 0.90M 1.69M
Cash 311.66M 243.78M 234.31M 228.63M 24.46M
Cash and equivalents - - - - -
Total current liabilities 163.78M 78.88M 53.77M 134.54M 19.89M
Current deferred revenue 123.24M - 49.41M - -
Net debt -118.09400M -52.13700M -42.32500M -34.38100M 73.49M
Short term debt 15.00M 2.00M 2.00M - -
Short long term debt 15.00M 2.00M 2.00M - -
Short long term debt total 193.57M 191.65M 191.98M 194.25M 97.95M
Other stockholder equity 610.27M 675.12M 640.10M 585.37M 411.28M
Property plant equipment - 0.57M 0.82M 0.94M 1.33M
Total current assets 451.07M 400.29M 284.44M 262.89M 31.50M
Long term investments 72.17M 22.57M - - -
Net tangible assets - 241.88M 42.59M -65.16300M -495.04700M
Short term investments 41.80M 79.33M - - -
Net receivables 74.14M 54.74M 34.84M 22.18M 4.25M
Long term debt 178.57M 189.65M 189.98M 194.25M 97.95M
Inventory 5.36M 4.30M 4.43M 3.82M 1.09M
Accounts payable 17.73M 3.79M 1.00M 2.56M 6.36M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.00200M -0.15100M - -427.07400M -
Additional paid in capital - - - - -
Common stock total equity - 0.00100M 0.00100M 0.00100M -
Preferred stock total equity - - - - -
Retained earnings total equity - -272.13000M -453.59800M -488.19500M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 6.57M 3.55M 4.26M 0.90M 1.69M
Deferred long term asset charges - - - - -
Non current assets total 360.38M 273.58M 149.00M 164.18M 75.21M
Capital lease obligations - - - - -
Long term debt total - 189.65M 189.98M 194.25M -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -141.83200M -100.29800M -2.00200M -127.14900M -1.34200M
Change to liabilities 23.20M -1.55500M -3.80400M 4.90M -0.61000M
Total cashflows from investing activities -141.83200M -100.29800M -2.00200M -127.14900M -1.34200M
Net borrowings -2.00000M -0.50000M 97.46M 100.00M 100.00M
Total cash from financing activities 6.84M 7.42M 209.16M 143.77M 21.61M
Change to operating activities 12.87M 15.46M 12.83M 8.74M 0.45M
Net income 181.47M 34.60M -36.94400M -151.97700M -39.89800M
Change in cash 9.47M 5.68M 204.17M -58.81600M -18.52600M
Begin period cash flow 235.06M 229.38M 25.21M 84.02M 102.55M
End period cash flow 244.53M 235.06M 229.38M 25.21M 84.02M
Total cash from operating activities 144.47M 98.56M -2.98500M -75.43600M -38.79900M
Issuance of capital stock 0.00000M 30.00M 147.63M 50.00M 25.00M
Depreciation 23.39M 18.84M 10.24M 3.21M 0.18M
Other cashflows from investing activities -40.00000M -100.00000M -2.00000M - -
Dividends paid - - 200.30M - -
Change to inventory 0.14M -0.60900M -2.73500M -1.08800M -1.08800M
Change to account receivables -19.89700M -12.66700M -17.92200M -4.25500M -4.25500M
Sale purchase of stock 8.84M 39.07M -0.16700M 0.00000M -3.20000M
Other cashflows from financing activities 8.84M 199.92M 382.58M 143.77M 24.82M
Change to netincome -58.24400M 42.25M 32.94M 64.45M 1.08M
Capital expenditures 40.17M 100.30M 2.00M 127.15M 1.34M
Change receivables -19.89700M -12.66700M -17.92200M - -
Cash flows other operating -6.81600M -1.20900M -3.27700M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes 9.47M 5.68M 204.17M - -
Change in working capital -4.10600M 0.63M -11.62800M 8.29M -0.16400M
Stock based compensation 26.17M 15.66M 4.69M 9.91M 1.08M
Other non cash items 3.49M 2.68M 4.91M 55.13M -
Free cash flow 104.29M -1.74100M -4.98700M -202.58500M -40.14100M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
HRMY
Harmony Biosciences Holdings		 0.56 1.74% 32.66 12.90 11.17 2.88 3.59 2.60 6.84
NVO
Novo Nordisk A/S		 1.81 4.32% 43.81 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.23% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 12.68 2.96% 441.01 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.44 1.04% 625.39 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Harmony Biosciences Holdings

630 West Germantown Pike, Plymouth Meeting, PA, United States, 19462

Key Executives

Name Title Year Born
Mr. Jeffrey S. Aronin Founder & Non-Exec. Chairman 1968
Mr. John Charles Jacobs M.B.A. Pres, CEO & Director 1967
Mr. Sandip S. Kapadia CPA, M.B.A. Exec. VP & CFO 1970
Dr. Jeffrey M. Dayno M.D. Exec. VP & Chief Medical Officer 1957
Mr. Jeffrey Dierks M.B.A. Exec. VP & Chief Commercial Officer 1972
Mr. Andrew Serafin J.D., M.B.A. Exec. VP & Chief Strategy Officer 1975
Mr. David Bradshaw Head of Technical Operations NA
Ms. Sharon Goldbach Head of Facilities Operations & Exec. Admin. NA
Luis Sanay Head of Investor Relations NA
Mr. Christian Ulrich Gen. Counsel NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.